2023-05-04 09:00:00
Bronchiolitis is a dangerous disease in infants, but not only. Each year in the United States, approximately 10,000 people over the age of 65 die from respiratory syncytial virus (RSV), which in particular causes bronchiolitis. ” THE the elderlyespecially those with underlying health conditions, such as heart or lung disease or a weakened immune system, run a high risk of severe illness from RSV “said Peter Marks, director of the FDA (Food and drug administration) in a press release (source 1). “It is an important public health success in preventing a disease that can be life-threatening,” he said.
The vaccine Arexvy, developed by the pharmaceutical giant GSK, was authorized by the United States Medicines Agency on Wednesday May 3 for adults aged 60 and over. It’s regarding world’s first licensed RSV vaccine for the elderly. The phase three clinical trial was carried out on around 25,000 people, half of whom received the vaccine. This one showed up 83% efficient to prevent upper respiratory tract infections, and 94% to prevent a severe form. Arexvy should be available before the next epidemic season 2023/2024, announced the British laboratory in a press release (source 2).
Soon a vaccine once morest bronchiolitis in France?
Last week, the Arexvy vaccine received a favorable opinion from the European Medicines Agency. “A final European regulatory decision is expected in the coming months”, mentions GSK in the press release. It should then be authorized in France to be marketed there.
Other laboratories, such as Pfizer or Moderna, are also developing an RSV vaccine for the elderly.
For infants, a preventive treatment once morest bronchiolitis, developed by Sanofi and Astra Zeneca, was authorized in November 2022 by Europe, but not yet in France.
1683227371
#vaccine #bronchiolitis #authorized #United #States #world
